SSG
INSY

Summit Securities Group’s Insys Therapeutics, Inc. INSY Stock Holding History

Summit Securities Group’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-400
Closed -$8K – 687
2014
Q1 		$8K Buy
+400
New +$7.93K ﹤0.01% 279
2013
Q4 		– Sell
-93
Closed -$1K – 622
2013
Q3 		$1K Sell
93
-2,907
-97% -$23.9K ﹤0.01% 389
2013
Q2 		$14K Buy
+3,000
New +$11K 0.01% 282

Other funds holding INSY

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
BTP
Bloom Tree Partners New York $215M AUM 17.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Summit Securities Group's INSY Position: Q2 2014 in Review

Summit Securities Group sold out of Insys Therapeutics, Inc. (INSY) in Q2 2014, closing a stake of 400 shares — an estimated $8K sold.

Summit Securities Group first reported a position in INSY in Q2 2013 and held it in 3 quarters. The position peaked at $14K in Q2 2013. 99 funds tracked by Wall St. Rank hold INSY as of Q2 2014.

  • Summit Securities Group reported no remaining Insys Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • Summit Securities Group sold 400 Insys Therapeutics, Inc. shares in Q2 2014, an estimated $8K.
  • Summit Securities Group first reported a position in Insys Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
  • Summit Securities Group's Insys Therapeutics, Inc. position peaked at $14K in Q2 2013.
  • 99 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q2 2014.

Based on Summit Securities Group's 13F filing for Q2 2014, filed 12 Aug 2014.